Of note, we did observe reduced phospho-ERK but not phospho-MEK signalling in AML cells treated with the combination raising a question as to whether the synergy arises at the level of the lysosome where scaffolding of MEK and ERK occurs and where too mTORC1 is located. The gene discussed is MAP2K7; the disease is acute myeloid leukemia.